文献速递胸部肿瘤

卡马替尼在经MET抑制剂治疗的MET异常肺癌中的2期研究

A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
PubMed 文献 · J Thorac Oncol · 2021-02-03

该2期研究评估卡马替尼400mg每日两次在既往接受过MET抑制剂治疗的晚期MET扩增或MET外显子14跳跃突变NSCLC患者中的疗效,共纳入20例(15例跳跃突变,5例扩增),全部既往接受过克唑替尼。客观缓解率为10%,疾病控制率80%,中位无进展生存期5.5个月,中位总生存期11.3个月。结论认为卡马替尼在克唑替尼经治患者中活性有限,可能与耐药机制重叠有关。

要点

  • 卡马替尼在克唑替尼经治MET异常NSCLC中客观缓解率仅10%,疾病控制率80%。
  • 因不耐受停用克唑替尼的5例患者疾病控制率83%,其中2例肿瘤缩小25%和28%。
  • 基线血浆可检出MET D1228/Y1230突变和MAPK通路改变,进展后出现新发或持续MET突变及MAPK改变。

核心结论

  • 卡马替尼在克唑替尼经治的MET异常晚期NSCLC中活性有限,客观缓解率为10%。

研究设计与样本

  • 单臂2期研究,2016年5月至2019年11月纳入20例晚期NSCLC患者,其中MET外显子14跳跃突变15例、MET扩增5例。
  • 所有患者既往接受过克唑替尼,其中3例还接受过其他MET靶向治疗;卡马替尼剂量为400mg每日两次。
  • 主要终点为客观缓解率,次要终点包括无进展生存期、疾病控制率、颅内缓解率和总生存期,并分析循环肿瘤DNA探索耐药机制。

主要发现

  • 2例(10%)达到客观缓解,14例疾病稳定,疾病控制率为80%。
  • 5例因不耐受停用克唑替尼的患者疾病控制率为83%,其中2例最佳肿瘤缩小分别为-25%和-28%。
  • 4例可测量脑转移患者的颅内疾病控制率为100%,未观察到颅内客观缓解。
  • 中位无进展生存期为5.5个月(95%CI:1.3-11.0),中位总生存期为11.3个月(95%CI:5.5-未达到)。
  • 克唑替尼治疗后、卡马替尼治疗前血浆中反复检出MET D1228和Y1230突变及MAPK改变;卡马替尼进展时血浆中新发和持续存在MET突变及MAPK通路改变。

临床怎么用

  • 对于克唑替尼经治的MET异常NSCLC,卡马替尼单药客观缓解率有限,需权衡获益与耐药机制。
  • 因不耐受而非疾病进展停用克唑替尼的患者,后续卡马替尼仍可能获得疾病控制。
  • 治疗前血浆检出MET D1228/Y1230突变或MAPK改变可能提示卡马替尼耐药,需考虑联合或换用策略。

局限性

  • 样本量小(共20例),为单臂2期研究,无对照。
  • MET扩增患者仅5例,跳跃突变患者15例,亚组结果解读受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Capmatinib is approved for MET exon 14-altered NSCLC on the basis of activity in targeted therapy-naive patients. We conducted a phase 2 study to assess the efficacy of capmatinib in patients previously treated with a MET inhibitor. METHODS: Patients with advanced NSCLC harboring MET amplification or MET exon 14 skipping alterations received capmatinib 400 mg twice daily. The primary end point was the objective response rate. Secondary end points included progression-free survival, disease control rate (DCR), intracranial response rate, and overall survival. Circulating tumor DNA was analyzed to identify capmatinib resistance mechanisms. RESULTS: A total of 20 patients were enrolled between May 2016 and November 2019, including 15 patients with MET skipping alterations and five patients with MET amplification. All patients had received crizotinib; three had also received other MET-directed therapies. The median interval between crizotinib and capmatinib was 22 days (range: 4-374). Two patients (10%) achieved an objective response to capmatinib and 14 had stable disease, yielding a DCR of 80%. Among five patients who discontinued crizotinib for intolerance, the DCR was 83%, including two patients with the best tumor shrinkage of -25% and -28%. Intracranial DCR among four patients with measurable brain metastases was 100%, with no observed intracranial objective responses. Overall, the median progression-free survival and overall survival were 5.5 (95% confidence interval: 1.3-11.0) and 11.3 (95% confidence interval: 5.5-not reached) months, respectively. MET D1228 and Y1230 mutations and MAPK alterations were recurrently detected in postcrizotinib, precapmatinib plasma. New and persistent MET mutations and MAPK pathway alterations were detected in plasma at progression on capmatinib. CONCLUSIONS: Capmatinib has modest activity in crizotinib-pretreated MET-altered NSCLC, potentially owing to overlapping resistance mechanisms.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Dagogo-Jack I, Moonsamy P, Gainor JF, et al. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol. 2021. PMID: 33545388. doi:10.1016/j.jtho.2021.01.1605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。